These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1181 related articles for article (PubMed ID: 33746596)

  • 21. Recent updates on CAR T clinical trials for multiple myeloma.
    Lin Q; Zhao J; Song Y; Liu D
    Mol Cancer; 2019 Nov; 18(1):154. PubMed ID: 31684964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
    Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
    J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis.
    Pereira R; Bergantim R
    Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.
    Xiang X; He Q; Ou Y; Wang W; Wu Y
    Front Pharmacol; 2020; 11():544754. PubMed ID: 33343342
    [No Abstract]   [Full Text] [Related]  

  • 25. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
    Banerjee R; Marsal J; Huang CY; Lo M; Thiruvengadam SK; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
    Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
    Gagelmann N; Dima D; Merz M; Hashmi H; Ahmed N; Tovar N; Oliver-Caldés A; Stölzel F; Rathje K; Fischer L; Born P; Schäfer L; Albici AM; Schub N; Kfir-Erenfeld S; Assayag M; Asherie N; Wulf GG; Kharboutli S; Müller F; Shune L; Davis JA; Anwer F; Vucinic V; Platzbecker U; Ayuk F; Kröger N; Khouri J; Gurnari C; McGuirk J; Stepensky P; Abdallah AO; Fernández de Larrea C
    J Clin Oncol; 2024 May; 42(14):1665-1675. PubMed ID: 38358946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
    Li C; Cao W; Que Y; Wang Q; Xiao Y; Gu C; Wang D; Wang J; Jiang L; Xu H; Xu J; Zhou X; Hong Z; Wang N; Huang L; Zhang S; Chen L; Mao X; Xiao M; Zhang W; Meng L; Cao Y; Zhang T; Li J; Zhou J
    Clin Transl Med; 2021 Mar; 11(3):e346. PubMed ID: 33784005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
    Qu X; An G; Sui W; Wang T; Zhang X; Yang J; Zhang Y; Zhang L; Zhu D; Huang J; Zhu S; Yao X; Li J; Zheng C; Zhu K; Wei Y; Lv X; Lan L; Yao Y; Zhou D; Lu P; Qiu L; Li J
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
    Li C; Xu J; Luo W; Liao D; Xie W; Wei Q; Zhang Y; Wang X; Wu Z; Kang Y; Zheng J; Xiong W; Deng J; Hu Y; Mei H
    Leukemia; 2024 Jan; 38(1):149-159. PubMed ID: 37848634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAR T cell therapies for patients with multiple myeloma.
    Mikkilineni L; Kochenderfer JN
    Nat Rev Clin Oncol; 2021 Feb; 18(2):71-84. PubMed ID: 32978608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis.
    Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M
    Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function.
    He SL; Cheng YH; Wang D; Xu ML; Que YM; Xu YJ; Ma LM; Li CR; Zhou JF
    Curr Med Sci; 2021 Jun; 41(3):474-481. PubMed ID: 34169427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
    Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
    Front Immunol; 2021; 12():609421. PubMed ID: 33767695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis.
    Akhtar OS; Sheeba BA; Azad F; Alessi L; Hansen D; Alsina M; Baz R; Shain K; Grajales Cruz A; Castaneda Puglianini O; Liu H; Blue B; Nishihori T; Al Jumayli M; Extermann M; Locke FL; Mhaskar R; Freeman CL
    J Geriatr Oncol; 2024 Mar; 15(2):101628. PubMed ID: 37723045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
    Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
    J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.
    Wang T; Yang Y; Ma L; Feng R; Li J; Zhang C; Bai J; Ding Y; Liu G; Wu F; Lu X; Feng S; Li Z; He T; Li J; Liu H
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39313307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
    Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].
    Gao SQ; Mu J; Li X; Wang J; Cui R; Li JY; Sui T; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):378-382. PubMed ID: 38951066
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.